RU2661406C2 - Способы лечения заболеваний, ассоциированных с s. aureus - Google Patents

Способы лечения заболеваний, ассоциированных с s. aureus Download PDF

Info

Publication number
RU2661406C2
RU2661406C2 RU2015121617A RU2015121617A RU2661406C2 RU 2661406 C2 RU2661406 C2 RU 2661406C2 RU 2015121617 A RU2015121617 A RU 2015121617A RU 2015121617 A RU2015121617 A RU 2015121617A RU 2661406 C2 RU2661406 C2 RU 2661406C2
Authority
RU
Russia
Prior art keywords
seq
amino acid
antibody
acid sequence
aureus
Prior art date
Application number
RU2015121617A
Other languages
English (en)
Russian (ru)
Other versions
RU2015121617A (ru
Inventor
Брет СЕЛЛМАН
Кристин ТКАЧИК
Мелисса ХЭМИЛТОН
Лэй ХУА
Original Assignee
МЕДИММЬЮН, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МЕДИММЬЮН, ЭлЭлСи filed Critical МЕДИММЬЮН, ЭлЭлСи
Publication of RU2015121617A publication Critical patent/RU2015121617A/ru
Application granted granted Critical
Publication of RU2661406C2 publication Critical patent/RU2661406C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2015121617A 2012-11-06 2013-11-05 Способы лечения заболеваний, ассоциированных с s. aureus RU2661406C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
US61/723,128 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Publications (2)

Publication Number Publication Date
RU2015121617A RU2015121617A (ru) 2016-12-27
RU2661406C2 true RU2661406C2 (ru) 2018-07-16

Family

ID=50685101

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015121617A RU2661406C2 (ru) 2012-11-06 2013-11-05 Способы лечения заболеваний, ассоциированных с s. aureus

Country Status (13)

Country Link
US (3) US9845348B2 (enExample)
EP (1) EP2928490B1 (enExample)
JP (2) JP6506172B2 (enExample)
KR (3) KR20150092738A (enExample)
CN (2) CN112316135A (enExample)
AU (2) AU2013341421A1 (enExample)
BR (1) BR112015010126B1 (enExample)
CA (1) CA2890385C (enExample)
ES (1) ES2912267T3 (enExample)
MX (1) MX367082B (enExample)
RU (1) RU2661406C2 (enExample)
SG (2) SG11201503231YA (enExample)
WO (1) WO2014074470A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
HUE050985T2 (hu) 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
KR20150092738A (ko) * 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
EP3864040A1 (en) 2018-10-09 2021-08-18 Medimmune, LLC Antibodies directed against staphylococcus aureus leukotoxins
WO2020076789A2 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
TW202100549A (zh) 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 降低金黃色葡萄球菌在定殖的患者中之感染
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120201829A1 (en) * 2009-08-10 2012-08-09 Michael Rudolf Human Monoclonal Antibody Against S. Aureus Derived Alpha-Toxin and Its Use in Treating or Preventing Abscess Formation
WO2012109285A2 (en) * 2011-02-08 2012-08-16 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2012109167A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2719397A1 (en) * 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Use of alpha-toxin for treating and preventing staphylococcus infections
AU2008292897B2 (en) 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2453881A2 (en) * 2009-07-16 2012-05-23 Georgia Health Sciences University Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
KR20150092738A (ko) * 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120201829A1 (en) * 2009-08-10 2012-08-09 Michael Rudolf Human Monoclonal Antibody Against S. Aureus Derived Alpha-Toxin and Its Use in Treating or Preventing Abscess Formation
WO2012109285A2 (en) * 2011-02-08 2012-08-16 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2012109167A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides

Also Published As

Publication number Publication date
KR20210083389A (ko) 2021-07-06
US20200109191A1 (en) 2020-04-09
JP6926138B2 (ja) 2021-08-25
JP2019142888A (ja) 2019-08-29
CN112316135A (zh) 2021-02-05
BR112015010126A2 (enExample) 2017-08-22
US20190002540A1 (en) 2019-01-03
JP6506172B2 (ja) 2019-04-24
JP2015536951A (ja) 2015-12-24
SG10201703677VA (en) 2017-06-29
MX367082B (es) 2019-08-05
EP2928490A1 (en) 2015-10-14
EP2928490B1 (en) 2022-03-30
HK1215173A1 (zh) 2016-08-19
AU2018236849B2 (en) 2020-05-21
KR20200102533A (ko) 2020-08-31
US10457724B2 (en) 2019-10-29
MX2015005481A (es) 2016-01-14
AU2018236849A1 (en) 2018-10-18
KR102272744B1 (ko) 2021-07-06
CA2890385A1 (en) 2014-05-15
EP2928490A4 (en) 2016-11-02
CN104780934A (zh) 2015-07-15
BR112015010126B1 (pt) 2022-11-01
SG11201503231YA (en) 2015-05-28
WO2014074470A1 (en) 2014-05-15
ES2912267T3 (es) 2022-05-25
US9845348B2 (en) 2017-12-19
KR20150092738A (ko) 2015-08-13
US20160257733A1 (en) 2016-09-08
CA2890385C (en) 2022-07-12
US10759849B2 (en) 2020-09-01
AU2013341421A1 (en) 2015-06-04
RU2015121617A (ru) 2016-12-27

Similar Documents

Publication Publication Date Title
US10759849B2 (en) Methods of treating S. aureus-associated diseases
KR102288394B1 (ko) 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
US20150044168A1 (en) Treatment of Multiple Sclerosis With Anti-CD19 Antibody
US12570744B2 (en) Bispecific PD-1 and TIGIT binding proteins and uses thereof
US20240109961A1 (en) Treatment of chronic prurigo
HK1215173B (en) Methods of treating s. aureus-associated diseases
TW202506180A (zh) 用於癌症治療之pd-1/tigit結合蛋白
TW202511292A (zh) 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白
WO2025250726A1 (en) Anti-kit antibody dosing and methods
CN119654169A (zh) 抗体-药物缀合物和双特异性检查点抑制剂的组合
RU2808018C2 (ru) Антитела к поверхностным детерминантам s. aureus
CN117120089A (zh) 慢性痒疹的治疗